Implications of the Gut Microbiome in Parkinson's Disease

Abstract

Parkinson's disease is a common neurodegenerative disorder that presents with nonmotor and motor symptoms. The nonmotor manifestations of Parkinson's disease often begin years before the motor symptoms. Autopsy studies, including both Parkinson's disease patients and matched controls, demonstrated that α‐synuclein aggregates in Parkinson's disease patients can be found in both the substantia nigra and the enteric nervous system. Therefore, it has been hypothesized that the pathological process that leads eventually to Parkinson's disease might initially take place in the enteric nervous system years before the appearance of motor features. The gut microbiome plays essential roles in the development and maintenance of different body systems. Dysbiosis of the normal gut microbiome is thought to be associated with pathophysiologic changes not only in the gastrointestinal system itself but also in the enteric and central nervous systems. These changes are thought to ultimately cause loss of dopaminergic neurons via various mechanisms including the release of neurotoxins into the systemic circulation, decreased production of neuroprotective factors, and triggering inflammatory and autoimmune responses. In this review, we review the gut microbiome changes in Parkinson's disease and discuss the mechanisms by which gut microbiome dysbiosis may be a contributing factor to the pathophysiology of Parkinson's disease. © 2020 International Parkinson and Movement Disorder Society

Nutritional combinatorial impact on the gut microbiota and plasma short-chain fatty acids levels in the prevention of mammary cancer in Her2/neu estrogen receptor-negative transgenic mice

“…The copyright holder for this preprint (which this version posted June 8, 2020. ; https://doi.org/10.1101/2020.06.08.139865 doi: bioRxiv preprint health [56] and alterations in composition and diversity of colonizing microbial communities have been associated with pathogenesis of a vast number of disorders over the past decade [57][58][59][60]. We investigated the impact of early life consumption of these dietary compounds on the inhibition of breast cancer, intestinal communities and their derived metabolites in Her2/neu mice by analyzing the gut microbiota and plasma SCFAs profiles.…”

Approach to the patient with early Parkinson disease: diagnosis and management

“…These and other observations have led to the proposition that alpha‐synuclein pathology may propagate from the gut, via the vagus nerve, to the CNS 19 . The potential role of the gut microbiome in triggering and/or promoting the development of alpha‐synuclein pathology in the enteric nervous system is an area of active study 20 …”

Development of early diagnosis of Parkinson's disease: Illusion or reality?

“…So, microbiota toxins upon entry into the body promote α-synucleinopathy and the spread of an abnormal α-synuclein through the body in a prion-like manner. 24,44,45 In turn, heavy metals that enter intranasally in the brain accumulate in dopaminergic neurons of the substantia nigra, causing oxidative stress and neurodegeneration. 16,24 The toxicity of some exogenous factors depends on the genetic polymorphism of cytochrome P450 2D6 (CYP2D6), an enzyme involved in their metabolism.…”